SEC Filing Document

Company: Synergy CHC Corp.
Ticker: SNYR
CIK: 1562733
Filing Type: S-1
Document Type: EX-1.1
Date Filed: 2025-08-15
Accession Number: 0001213900-25-077458
Exchange: Nasdaq
SIC Code: 2833
SIC Description: Medicinal Chemicals & Botanical Products
URL: https://www.sec.gov/Archives/edgar/data/1562733/000121390025077458/ea024071103ex1-1_synergy.htm

Chunk 0 of 19
Word Count: 1426
Character Count: 9342

Document Content:

Exhibit 1.1

SYNERGY CHC CORP.

UNDERWRITING AGREEMENT

[●] Shares of Common Stock

August [●], 2025

Bancroft Capital, LLC

501 Office Center Drive, Suite 130

Fort Washington, PA 19034

Attention: Jason Diamond, Head of Investment Banking

Ladies and Gentlemen:

Synergy CHC Corp., a company
incorporated under the law of the State of Nevada (the “Company”), proposes, subject to the terms and conditions set
forth herein, to issue and sell [●] authorized but unissued shares of common stock, par value $0.00001 per share (the “Common
Stock”), of the Company (the “Shares”) to Bancroft Capital, LLC (the “Representative”).
If there are no underwriters other than the Representative, all references herein to multiple “Underwriters” shall
be disregarded, and all references to the “Representative” shall be deemed to refer to the “Underwriter.”
If there are multiple Underwriters, the Company proposes to issue and sell the Shares severally and not jointly to the Underwriters. The
Company has also granted to the Underwriters an option to purchase up to an additional number of authorized but unissued Shares (the “Additional
Shares”) equal to fifteen percent (15%) of the total number of Shares sold in the offering contemplated hereby (the “Offering”),
on the terms and for the purposes set forth in Section 4(e) hereof. The Shares, together with the Representative Warrants (as defined
below), the Additional Shares, and the shares of Common Stock issuable upon exercise thereof (the “Representative Warrant Shares”),
are collectively referred to herein as the “Securities”.

The Company and the Representative
hereby confirm their agreement (this “Agreement”) as follows:

1. Registration Statement
and Prospectus.

The Company has prepared and
filed with the Securities and Exchange Commission (the “Commission”) a registration statement covering the Shares on
Form S-1 (File No. 333-[●]) under the Securities Act of 1933, as amended (the “Securities Act”), and the rules
and regulations (the “Rules and Regulations”) of the Commission thereunder, and such amendments to such registration
statement (including post effective amendments) as may have been required to the date of this Agreement. Such registration statement,
as amended (including any post effective amendments), has been declared effective by the Commission. Such registration statement, including
amendments thereto (including post effective amendments thereto) at the time of effectiveness thereof (the “Effective Time”),
the exhibits and any schedules thereto at the Effective Time or thereafter during the period of effectiveness and the documents and information
otherwise deemed to be a part thereof or included therein by the Securities Act or otherwise pursuant to the Rules and Regulations at
the Effective Time or thereafter during the period of effectiveness, is herein called the “Registration Statement.”
If the Company has filed or files an abbreviated registration statement pursuant to Rule 462(b) under the Securities Act (the “Rule
462 Registration Statement”), then any reference herein to the term Registration Statement shall include such Rule 462 Registration
Statement. Any preliminary prospectus included in the Registration Statement or filed with the Commission pursuant to Rule 424(a) under
the Securities Act is hereinafter called a “Preliminary Prospectus”. The Preliminary Prospectus relating to the Shares
that was included in the Registration Statement immediately prior to the pricing of the Offering is hereinafter called the “Pricing
Prospectus.”

The Company is filing with
the Commission pursuant to Rule 424(b) under the Securities Act a final prospectus covering the Shares, which includes the information
permitted to be omitted therefrom at the Effective Time by Rule 430A under the Securities Act. Such final prospectus, as so filed, is
hereinafter called the “Final Prospectus.” The Final Prospectus, the Pricing Prospectus and any preliminary prospectus
in the form in which they were included in the Registration Statement or filed with the Commission pursuant to Rule 424 under the Securities
Act is hereinafter called a “Prospectus”.

2. Representations and
Warranties of the Company Regarding the Offering.

(a) The Company represents and
warrants to, and agrees with, the Underwriters, as of the date hereof, as of the Closing Date (as defined in Section 4(d) of this Agreement)
and as of any Option Closing Date (as defined in Section 4(f) of this Agreement) as follows (except where a representation and warranty
speaks as of a specific date as indicated below):

(i) No Material
Misstatements or Omissions. At the Effective Time, on the date hereof, on the Closing Date and any Option Closing Date, the Registration
Statement and any post-effective amendment thereto complied or will comply in all material respects with the requirements of the Securities
Act and the Rules and Regulations and did not, does not, and will not, as the case may be, contain any untrue statement of a material
fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances
under which they were made, not misleading. The Time of Sale Disclosure Package (as defined in Section 2(a)(vi)(A)(1) below) as of [9:00
a.m., Eastern time] (the “Applicable Time”) on the date hereof, on the Closing Date and the Final Prospectus, as amended
or supplemented, as of its date, at the time of filing pursuant to Rule 424(b) under the Securities Act, on the Closing Date and any individual
Written Testing-the-Waters Communication (as defined in Section 2(a)(v)), when considered together with the Time of Sale Disclosure Package,
did not, does not and will not contain any untrue statement of a material fact or omit to state a material fact required to be stated
therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading. The representations
and warranties set forth in the two immediately preceding sentences shall not apply to statements in or omissions from the Registration
Statement, the Time of Sale Disclosure Package or any Prospectus in reliance upon, and in conformity with, written information furnished
to the Company by the Representative specifically for use in the preparation thereof, which written information is described in Section
7(f). The Registration Statement contains all exhibits and schedules required to be filed by the Securities Act or the Rules and Regulations.
No order preventing or suspending the effectiveness or use of the Registration Statement or any Prospectus is in effect and no proceedings
for such purpose have been instituted or are pending, or, to the knowledge of the Company, are contemplated or threatened by the Commission.

(ii) Marketing
Materials. The Company has not distributed any prospectus or other offering material in connection with the Offering and sale of the
Shares other than the Time of Sale Disclosure Package and the roadshow or investor presentations delivered to and approved by the Representative
for use in connection with the marketing of the Offering of the Securities (the “Marketing Materials”).

(iii) Smaller
Reporting Company. As of the time of filing of the Registration Statement, the Applicable Time, the date hereof and the Closing
Date, the Company was and is a “smaller reporting company”, as defined in Item 10(f)(1) of Regulation S-K and Rule 12b-2 of
the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

(iv) Ineligible
Issuer. At the time of filing the Registration Statement and any post-effective amendment thereto, at the time of effectiveness
of the Registration Statement and any amendment thereto, at the earliest time thereafter that the Company or another offering participant
made a bona fide offer (within the meaning of Rule 164(h)(2) of the Securities Act Regulations) of the Shares and at the date hereof,
the Company was not and is not an “ineligible issuer,” as defined in Rule 405 of the Securities Act Regulations, without taking
account of any determination by the Commission pursuant to such rule that it is not necessary that the Company be considered an ineligible
issuer.

(v) Testing-the-Waters
Communications. Except as approved in writing by the Representative, the Company (i) has not alone engaged in any Testing-the-Waters
Communication and (ii) has not authorized anyone to engage in Testing-the-Waters Communications. The Company has not distributed any Testing-the-Waters
Communication that is a written communication within the meaning of Rule 405 under the Securities Act
(“Written Testing-the-Waters Communications”), other than those previously provided to the Representative and
listed on Schedule IV hereto. “Testing-the-Waters Communication” means any oral
or written communication with potential investors undertaken in reliance on Section 5(d) of the Securities Act.
Each Written Testing-the-Waters Communication, did not, as of the Applicable Time, and at
all times through the completion of the public offer and sale of Shares will not, include
any information that conflicted, conflicts or will conflict with the information contained in the Registration Statement, the Time
of Sale Disclosure Package and the Final Prospectus.

(vi) Accurate Disclosure.